Increased Expression of Interleukin-6 Family Members and Receptors in Urinary Bladder with Cyclophosphamide-Induced Bladder Inflammation in Female Rats by Girard, Beatrice M. et al.
www.frontiersin.org  February 2011  | Volume 5  | Article 20  |  1
Original research article
published: 22 February 2011
doi: 10.3389/fnins.2011.00020
Increased expression of interleukin-6 family members and 
receptors in urinary bladder with cyclophosphamide-induced 
bladder inflammation in female rats
Beatrice M. Girard1, Bopaiah P . Cheppudira2, Susan E. Malley2, Kristin C. Schutz1, Victor May1 and  
Margaret A. Vizzard1,2*
1  Department of Anatomy and Neurobiology, University of Vermont College of Medicine, Burlington, VT, USA
2  Department of Neurology, University of Vermont College of Medicine, Burlington, VT, USA
Recent studies suggest that janus-activated kinases–signal transducer and activator of 
transcription signaling pathways contribute to increased voiding frequency and referred pain 
of cyclophosphamide (CYP)-induced cystitis in rats. Potential upstream chemical mediator(s) 
that may be activated by CYP-induced cystitis to stimulate JAK/STAT signaling are not known in 
detail. In these studies, members of the interleukin (IL)-6 family of cytokines including, leukemia 
inhibitory factor (LIF), IL -6, and ciliary neurotrophic factor (CNTF) and associated receptors, IL -6 
receptor (R) α, LIFR, and gp130 were examined in the urinary bladder in control and CYP-treated 
rats. Cytokine and receptor transcript and protein expression and distribution were determined 
in urinary bladder after CYP-induced cystitis using quantitative, real-time polymerase chain 
reaction (Q-PCR), western blotting, and immunohistochemistry. Acute (4 h; 150 mg/kg; i.p.), 
intermediate (48 h; 150 mg/kg; i.p.), or chronic (75 mg/kg; i.p., once every 3 days for 10 days) 
cystitis was induced in adult, female Wistar rats with CYP treatment. Q-PCR analyses revealed 
significant (p ≤ 0.01) CYP duration- and tissue- (e.g., urothelium, detrusor) dependent increases 
in LIF , IL -6, IL -6Rα, LIFR, and gp130 mRNA expression. Western blotting demonstrated significant 
(p ≤ 0.01) increases in IL -6, LIF , and gp130 protein expression in whole urinary bladder with CYP 
treatment. CYP-induced cystitis significantly (p ≤ 0.01) increased LIF-immunoreactivity (IR) in 
urothelium, detrusor, and suburothelial plexus whereas increased gp130-IR was only observed 
in urothelium and detrusor. These studies suggest that IL -6 and LIF may be potential upstream 
chemical mediators that activate JAK/STAT signaling in urinary bladder pathways.
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Although the etiology and pathogenesis of BPS/IC are unknown, 
numerous theories including; infection, inflammation, autoim-
mune disorder, toxic urinary agents, urothelial dysfunction, and 
neurogenic causes have been proposed (Petrone et al., 1995; Ho 
et al., 1997; Johansson et al., 1997; Driscoll and Teichman, 2001; 
Sant and Hanno, 2001). We have hypothesized that pain associated 
with BPS/IC involves an alteration of visceral sensation/bladder 
sensory physiology. Altered visceral sensations from the urinary 
bladder (i.e., pain at low or moderate bladder filling) that accom-
pany BPS/IC (Petrone et al., 1995; Ho et al., 1997; Johansson et al., 
1997; Driscoll and Teichman, 2001; Sant and Hanno, 2001) may 
be mediated by many factors including changes in the properties 
of peripheral bladder afferent pathways such that bladder afferent 
neurons respond in an exaggerated manner to normally innocu-
ous stimuli (allodynia). These changes may be mediated, in part, 
by inflammatory changes in the urinary bladder. Among potential 
mediators of inflammation, neurotrophins (e.g., nerve growth fac-
tor) have been implicated in the peripheral sensitization of noci-
ceptors (Lindsay and Harmar, 1989; Dray, 1995; Dinarello, 1997). 
Pro-inflammatory cytokines also cause sensitization of polymo-
dal C-fibers (Dray, 1995) and facilitate A-beta input to the spinal 
cord (Woolf and Doubell, 1994; Baba et al., 1999). Several studies 
IntroductIon
Cytokine receptors signal predominantly through janus-activated 
kinases (JAK)–signal transducer and activator of transcription 
(STAT) pathways (Dziennis and Alkayed, 2008) and we recently 
demonstrated that cyclophosphamide (CYP)-induced cystitis of 
varying duration was associated with enhanced JAK–STAT sig-
naling (Cheppudira et al., 2009). STAT3 phosphorylation/acti-
vation was increased after CYP-induced cystitis (4 h, 48 h, and 
chronic; Cheppudira et al., 2009). Functionally, blockade of JAK2 
with AG490, a member of the tyrphostin family of tyrosine kinase 
inhibitors, significantly reduced bladder hyperreflexia and hind 
paw sensitivity in CYP-treated rats (Cheppudira et al., 2009). In 
aggregate, these studies demonstrated potential roles for JAK–STAT 
signaling pathways in contributing to bladder hyperreflexia and 
referred pain of CYP-induced bladder inflammation (Cheppudira 
et al., 2009). However, is not known what is/are the upstream chemi-
cal mediator(s) that are activated by CYP-induced cystitis to stimu-
late JAK/STAT signaling.
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is viewed 
as a one type of chronic pain syndrome characterized by pain, pres-
sure, or discomfort perceived to be bladder related with at least one 
urinary symptom such as urinary frequency (Hanno et al., 2010). Frontiers in Neuroscience  | Autonomic Neuroscience    February 2011  | Volume 5  | Article 20  |  2
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MaterIals and Methods
anIMals
Adult female, Wistar rats (200–225 g; Charles River, St. Constant, 
Canada) were used for this study. Rats were housed two per cage 
and maintained in standard laboratory conditions with free access 
to food and water. The University of Vermont Institutional Animal 
Care and Use Committee approved all animal use procedures (pro-
tocol 08-085).
InductIon of cyclophosphaMIde-Induced cystItIs
Rats were anesthetized under isoflurane (2%) and acute cystitis was 
induced with a single injection of CYP (150 mg/kg, i.p.) and rodents 
were used in studies at various time points (4 or 48 h) after treat-
ment (Cheppudira et al., 2008; Klinger and Vizzard, 2008; Klinger 
et al., 2008). Chronic CYP-cystitis was induced by administration 
of CYP (75 mg/kg; i.p.) once every 3 days for 8 days (Cheppudira 
et al., 2008; Klinger and Vizzard, 2008; Klinger et al., 2008). Control 
rodents received either saline injection or no treatment. Rats were 
euthanized using isoflurane (5%) and a thoracotomy.
real-tIMe quantItatIve reverse transcrIptIon-polyMerase 
chaIn reactIon (q-pcr)
Total RNA was extracted using the STAT-60 total RNA/mRNA 
isolation reagent (Tel-Test“B,” Friendswood, TX, USA) as previ-
ously described (Girard et al., 2002; Klinger et al., 2008; Arms et al., 
2010). One to 2 mg of RNA per sample was used to synthesize 
complementary DNA using a mix of random hexamer and oligo 
dT primers with M-MLV reverse transcriptase (Promega Corp.) in 
a 25-μl final reaction volume.
The quantitative PCR standards for all transcripts were prepared 
with the amplified IL-6, LIF, CNTF, gp130, IL-6Rα, LIFR cDNA 
products ligated directly into pCR2.1 TOPO vector using the TOPO 
TA cloning kit (Invitrogen). The nucleotide sequences of the inserts 
were verified by automated fluorescent dideoxy dye terminator 
sequencing (Vermont Cancer Center DNA Analysis Facility). To 
estimate the relative expression of the receptor transcripts, 10-fold 
serial dilutions of stock plasmids were prepared as quantitative 
standards. The range of standard concentrations was determined 
empirically.
Complementary DNA templates, diluted 10-fold to minimize 
the inhibitory effects of the reverse transcription reaction compo-
nents, were assayed using HotStart-IT SYBR Green qPCR Master 
Mix (USB, Cleveland, OH, USA) and 300 nM of each primer in a 
final 25 μl reaction volume (Girard et al., 2002; Klinger et al., 2008; 
Arms et al., 2010). The real-time quantitative PCR was performed 
(Applied Biosystems 7500 Fast real-time PCR system, Foster City, 
CA, USA; Girard et al., 2002; Klinger et al., 2008; Arms et al., 2010) 
using the following standard conditions: (i) serial heating at 94°C 
for 2 min; (ii) amplification over 40 cycles at 94°C for 15 s and 
60–64°C depending on primer sets for 30 s.
The amplified product from these amplification parameters 
was subjected to SYBR Green I melting analysis by ramping the 
temperature of the reaction samples from 60 to 95°C. A single 
DNA melting profile was observed under these dissociation assay 
conditions demonstrating amplification of a single unique product 
free of primer dimers or other anomalous products. The primer 
sequences used are described in Table 1.
from our laboratory have demonstrated increased cytokine and 
chemokine expression and beneficial effects of chemokine recep-
tor blockade in the urinary bladder after CYP-induced bladder 
inflammation (Malley and Vizzard, 2002). Furthermore, a recent 
study has also demonstrated upregulation of interleukin (IL)-6 
transcript and protein expression in the submucosal layer of blad-
der after CYP treatment in mice (Nishii et al., 2006). In addition, 
lipopolysaccharide, IL-1β, and tumor necrosis factor (TNF)-α 
induce production and/or secretion of IL-6 and IL-6 receptor (R) 
α in cultured, human detrusor smooth muscle cells (Bouchelouche 
et al., 2006; Neuhaus et al., 2007).
The IL-6 family of cytokines, through receptor interactions, 
induce transphosphorylation of the receptor-associated JAK, which 
in turn leads to phosphorylation of the down-stream STAT family 
of transcription factors (JAK–STAT pathway; Dziennis and Alkayed, 
2008). The IL-6 family of cytokines also activates mitogen-activated 
protein kinase (MAPK) signaling pathways and associated transcrip-
tion factors (Gadient and Patterson, 1999). Among the IL-6 family, 
leukemia inhibitory factor (LIF) is a multifunctional polypeptide 
cytokine/growth factor, related in both structure and mechanisms of 
action to the IL-6 family of cytokines (Knight, 2001). LIF is involved 
in neuronal developmental processes including neurogenesis, dif-
ferentiation, and survival (Kim et al., 2005). Numerous studies 
have also demonstrated elevated LIF in a variety of inflammatory 
conditions in humans and other animals (Alexander et al., 1994). 
Some reports suggest that LIF acts as a pro-inflammatory mediator 
(Sugiura et al., 2000), whereas other evidence indicates LIF func-
tions as an anti-inflammatory and analgesic cytokine (Ulich et al., 
1994; Banner et al., 1998). The closely related pleiotropic cytokine, 
IL-6, has numerous biological activities and is generally considered 
to be pro-inflammatory. The diverse biological activities of IL-6 
include promotion of neuronal survival, protection against neuronal 
damage, induction of neuronal differentiation, modulation of neu-
rotransmitter/neuromodulator synthesis, and modulation of pain. 
Receptors involved in the recognition of LIF and IL-6 include the 
non-signaling α-receptors, IL-6Rα, and the transducing receptors, 
gp130, and LIFR with gp130 being used by all IL-6 family members 
in different combinations (Hibi et al., 1990).
The purpose of this study was to determine potential upstream 
chemical mediator(s) that may be activated by CYP-induced cys-
titis to stimulate JAK/STAT signaling. Among the IL-6 family of 
cytokines, we have focused the current study on the urinary bladder 
expression and changes in transcript and protein expression of IL-6 
and LIF and associated receptors, IL-6Rα, LIFR, and gp130 with 
CYP-induced cystitis of varying duration. The CYP rodent model 
exhibits urinary bladder dysfunction (Hu et al., 2003, 2005; Klinger 
and Vizzard, 2008; Arms et al., 2010) and altered somatic sensitivity 
(Guerios et al., 2008; Studeny et al., 2008; Cheppudira et al., 2009) 
and permits a controlled analysis of some aspects of BPS/IC that 
are not feasible to address in the human population. Use of the CYP 
rat model is one way to examine the contribution of inflammatory 
and immune mediators to urinary bladder dysfunction and referred 
somatic sensitivity exhibited in the human syndrome of BPS/IC. A 
variety of techniques including immunohistochemistry in urinary 
bladder tissue sections and whole mounts with semiquantitation, 
quantitative real-time polymerase chain reaction (Q-PCR), and 
Western blotting approaches were used.www.frontiersin.org  February 2011  | Volume 5  | Article 20  |  3
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  detergent in 25 mM bicine, 150 mM sodium chloride (pH 7.6) 
containing a protease inhibitor mix (Sigma-Aldrich, St. Louis, MO, 
USA; 16 μg/ml benzamidine, 2 μg/ml leupeptin, 50 μg/ml lima 
bean trypsin inhibitor, and 2 μg/ml pepstatin A) and aliquots were 
removed for protein assay. Samples (25 μg) were suspended in sam-
ple buffer for fractionation on gels and subjected to SDS-PAGE. 
Proteins were transferred to nitrocellulose membranes, and effi-
ciency of transfer was evaluated. Membranes were blocked overnight 
in a solution of 5% milk, 3% bovine serum albumin in Tris-buffered 
saline with 0.1% Tween. For immunodetection, the following anti-
bodies were used overnight at 4°C: goat anti-LIF [1:200; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA (catalog #SC1336)], rab-
bit anti-gp130 (1:1000; Santa Cruz Biotechnology, Inc. (catalog 
#SC655), and rabbit anti-IL-6 (1:1000; Invitrogen Corporation, 
Carlsbad, CA, USA (catalog #ASC0062). Washed membranes were 
incubated in species-specific secondary antibodies for 2 h at room 
temperature for enhanced chemiluminescence detection (Pierce, 
Rockford, IL, USA). Blots were exposed to Biomax film (Kodak, 
Rochester, NY, USA) and developed. The intensity of each band 
was analyzed, and background intensities were subtracted using 
Un-Scan It software (Silk Scientific, Orem, UT, USA). Western 
blot analysis of actin (1:2000; Santa Cruz Biotechnology (catalog 
#SC1616R) in samples was used as a loading control. In this and 
previous studies (Corrow et al., 2010), we have used actin as a 
loading control as expression of actin protein was not changed in 
urinary bladder with CYP treatments.
IMMunohIstocheMIcal localIzatIon of lIf, Il-6, gp130 In 
urothelIuM
The  bladders  from  control,  acute  (4  h),  intermediate  (48  h), 
and chronic CYP-treated rats (n = 6 for each) were rapidly dis-
sected, weighed, post-fixed in 4% paraformaldehyde, and placed 
in ascending concentrations of sucrose (10–30%) in 0.1 M PBS 
for cryoprotection. Cryostat sections (20 μm) of urinary bladder 
were mounted on gelled (0.5%) microscope slides for on-slide 
processing as previously described (Yuridullah et al., 2006; Corrow 
and Vizzard, 2007; Cheppudira et al., 2008; Klinger and Vizzard, 
2008; Klinger et al., 2008). Briefly, sections were incubated with 
400 μl of goat anti-LIF [1:500; Santa Cruz Biotechnology, Inc. 
(SC1336)], rabbit anti-gp130 [1:1000; Santa Cruz Biotechnology, 
Inc. (catalog #SC655) or rabbit anti-IL-6 (1:200–1:5000; Invitrogen 
Corporation (catalog #ASC0062; #ARC0062); Santa Cruz (1:200–
1:3000; catalog #1265)] in 1% donkey or goat serum and 0.1 M 
phosphate-buffer overnight at room temperature. After washing 
(3 × 10 min) with 0.1 M PBS (pH 7.4) the tissues were incubated 
with Cy3-conjugated species-specific antibodies (1:500; Jackson 
Immunoresearch Laboratories, West Grove, PA, USA) for 2 h at 
room temperature, rinsed and mounted with antifade medium 
(Citifluor,  Fisher  Scientific,  Pittsburgh,  PA,  USA)  for  fluores-
cence microscopy. Control sections incubated in the absence of 
primary or secondary antibody were also processed and evalu-
ated for specificity or background staining levels. In the absence 
of primary antibody, no positive immunostaining was observed. 
Immunoabsorptions with LIF and gp130 peptide (5 μg/ml; Santa 
Cruz) and antisera in bladder sections resulted in no staining above 
background. Repeated attempts to localize IL-6-immunoreactivity 
(IR) in cryostat bladder sections with different antibodies and 
For data analyses, a standard curve was constructed by amplification 
of serially diluted plasmids containing the target sequence. Data were 
analyzed at the termination of each assay using sequence detection soft-
ware (Sequence Detection Software, version 1.3.1; Applied Biosystems, 
Norwalk, CT, USA). In standard assays, default baseline settings were 
selected. The increase in SYBR Green I fluorescence intensity (∆Rn) 
was plotted as a function of cycle number and the threshold cycle was 
determined by the software as the amplification cycle at which the ∆Rn 
first intersects the established baseline. All urothelium and detrusor 
data were normalized to housekeeping gene L32 transcript expression 
in the same cDNA templates (Table 1). Transcript levels in treated 
urothelium samples were expressed relative to control urothelium lev-
els. To allow ease of transcript level comparisons between different 
tissues, the normalized transcript levels in detrusor were expressed as 
a function of normalized control urothelium Q-PCR data.
splIt bladder preparatIon and assessMent of potentIal 
contaMInatIon of bladder layers
The urothelium + suburothelium was dissected from the detrusor 
smooth muscle using fine forceps under a dissecting microscope as 
previously described (Zvarova and Vizzard, 2005; Cheppudira et al., 
2008; Klinger et al., 2008). To confirm the specificity of our split blad-
der preparations, urothelium + suburothelium and detrusor samples 
were examined for the presence of α-smooth muscle actin (1:1000; 
Abcam, Cambridge, MA, USA) and uroplakin II (1:25; American 
Research Products, Belmont, MA, USA) by Western blotting or 
reverse transcription PCR (Corrow and Vizzard, 2007; Cheppudira 
et al., 2008). In urothelium + suburothelium layers, only uroplakin 
II was present (data not shown). Conversely, in detrusor samples, 
only α-smooth muscle actin was present (data not shown).
Western blottIng for Il-6, lIf, gp130 expressIon In Whole 
urInary bladder
Whole urinary bladders (control, 4 h, 48 h, and chronic; n = 6) were 
homogenized separately in tissue protein extraction agent (T-PER; 
Roche,  Indianapolis,  IN,  USA),  a  mild  zwitterionic    dialyzable 
Table 1 | Primer sequences.
Name  Location  Sequence
Rat IL -6  99U20  TTGCCTTCTTGGGACTGATG
Rat IL -6  261L20  GCCATTGCACAACTCTTTTC
IL -6Rα  29U20  AGCCAGTTGCCTTCTTGGGA
IL -6Rα  188L25  TTGCACAACTCTTTTCTCATTTCCA
Rat LIF  179U25  ATGCCCTCTTTATTTCCTATTACAC
Rat LIF  408L25  CATGACGTCTGTAGTCGCATTGAGT
LIFR  124U23  AATGGTCTTAAGAGAGGGGTACA
LIFR  215L20  TTTAACAGTTCCAGGGCTGA
gp130   1954U20  ACCCCCCAAGGCACAATTTTA
gp130   2549L24  ACCTGCTGCTGTTTCAGTCTGACA
Rat CNTF  3U21  TCACATTTCTTATTTGGACTA
Rat CNTF  662L21  GGCTACATCTGCTTATCTTTG
L32  83U20  CCTGGCGTTGGGATTGGTGA
L32  129L20  GAAAAGCCATCGTAGAAAGA
Primer names, locations, and sequences used in this study. Location of the primers 
corresponds to following coding sequences: MN_012589, MN_017020, MN_022196, 
MN_031048,  MN_001008725,  MN_013166,  XM_001056774.  IL,  interleukin;  R, 
receptor; LIF , leukemia inhibitory factor; CNTF , ciliary neurotrophic factor.Frontiers in Neuroscience  | Autonomic Neuroscience    February 2011  | Volume 5  | Article 20  |  4
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tion purposes and regional analyses of IR. The bladder was incubated 
for 1.5 h at room temperature in cold fixative (2% paraformalde-
hyde + 0.2% picric acid). Using fine tips forceps and iris scissors, the 
urothelium + suburothelium was dissected from the underlying detru-
sor smooth muscle with the aid of a dissecting microscope (Corrow and 
Vizzard, 2007; Klinger and Vizzard, 2008). Urothelium + suburothe-
lium and bladder musculature were processed for LIF- or gp130-IR 
(as described above). No gp130-IR was observed in the suburothe-
lial nerve plexus from control or experimental treatments (data not 
shown). In some whole mounts processed for LIF-IR, nerve fibers in 
the suburothelial nerve plexus were also stained with the pan neuronal 
marker, protein gene product (PGP 9.5; Abcam, Cambridge, MA, USA; 
1:15). After washing (3 × 10 min) with 0.1 M PBS (pH 7.4) the tissues 
were incubated with a cocktail of Cy3-conjugated donkey anti-goat 
(1:500) and Cy2-conjugated donkey anti-rabbit secondary antibody 
for 2 h at room temperature. After washing, the whole mounts were 
placed on microscope slides and coverslipped and were examined 
under an Olympus fluorescence photomicroscope as described above. 
Cy2 was visualized with a filter with an excitation range of 470–490 
and an emission range from 510 to 530.
assessMent of IMMunohIstocheMIcal staInIng In urInary 
bladder regIons
Immunohistochemistry and subsequent semi-quantification of LIF- 
or gp130-IR in bladder sections or whole mount preparations was per-
formed on control and experimental tissues simultaneously to reduce 
the incidence of staining variation that can occur between tissues 
processed on different days. Staining observed in experimental tissue 
was compared to that observed from experiment-matched negative 
controls. Urinary bladder sections or whole mounts exhibiting IR 
that was greater than the background level observed in experiment-
matched negative controls were considered positively stained.
fIgure preparatIon
Digital images were obtained using a CCD camera (MagnaFire SP; 
Optronics; Optical Analysis Corp., Nashua, NH, USA) and LG-3 
frame grabber (Scion Corp; Frederick, MD, USA). Exposure times, 
brightness and contrast were held constant when acquiring images 
from experimental or control animals processed and analyzed on 
the same day. Images were imported into a graphics-editing pro-
gram (Adobe Photoshop 7.0, Adobe Systems Incorporated, San 
Jose, CA, USA) assembled and labeled.
statIstIcs
All values are mean ± SEM. Data were compared using ANOVA. 
Percentage data from image analysis were arcsin transformed to 
meet the requirements of this statistical test. Animals, processed 
and analyzed on the same day, were tested as a block in the ANOVA. 
When F ratios exceeded the critical value (p ≤ 0.05), the Newman 
Keul’s post hoc test was used to compare experimental means.
results
Il-6, lIf, cntf transcrIpt expressIon In urothelIuM and 
detrusor sMooth Muscle WIth cyp-Induced cystItIs
The regulation of IL-6, LIF, and CNTF transcripts was examined 
by Q-PCR analyses (Figures 1A–C) in urothelium and detrusor 
smooth muscle. IL-6 transcript expression significantly (p ≤ 0.01) 
substantial trouble-shooting were not successful. Thus, data are 
not presented for immunohistochemical localization of IL-6-IR 
in urinary bladder.
vIsualIzatIon and seMI-quantItatIve analysIs of lIf-, gp130-Ir 
In urInary bladder
Urothelium
Leukemia inhibitory factor- and gp130-IR in bladder sections from 
control (n = 6) and CYP-treated groups (n = 6 each) was visualized 
and images were captured using an Olympus fluorescence photomi-
croscope. The filter was set with an excitation range of 560–569 nm 
and emission range of 610–655 nm for visualization of Cy3. Images 
were captured, acquired in tagged image file format and imported 
into image analysis software (Meta Morph, version 4.5r4, University 
Imaging, Downingtown, PA, USA; (Klinger et al., 2008; Arms et al., 
2010). The free hand drawing tool was used to select the urothelium 
and the urothelium was measured in total pixels area as previously 
described (Klinger et al., 2008; Arms et al., 2010). A threshold encom-
passing an intensity range of 100–250 grayscale values was applied 
to the region of interest in the least brightly stained condition first. 
The threshold was adjusted for each experimental series using con-
comitantly processed negative controls as a guide for setting back-
ground fluorescence. The same threshold was subsequently used for 
all images. IR was considered to be positive only when the staining for 
the marker of interest (LIF, gp130) exceeded the established threshold. 
Percent marker expression above threshold in the total area selected 
was calculated. LIF- and gp130-IR in the urothelium was consistent 
across all regions (dome, body, neck) of the urinary bladder examined 
for all conditions. Semi-quantification of LIF and gp130 expression 
in the urothelium is presented for the bladder neck region.
Detrusor smooth muscle
Visualization of LIF- and gp130-IR in detrusor smooth muscle of 
cryostat sections from control (n = 6) and CYP-treated groups (n = 6 
each) was identical to that described for the urothelium (above). 
Semi-quantification of IR in detrusor smooth muscle was performed 
as previously described (Klinger et al., 2007; Cheppudira et al., 2008) 
and modified from Brady et al. (2004). Grayscale images acquired 
in tagged image file format were imported into image analysis soft-
ware (Image J; Abramoff et al., 2004) and images were thresholded. 
Images of detrusor smooth muscle were acquired from the dome, 
body, and neck region of the urinary bladder in control and CYP 
treatment groups. A rectangle of fixed dimension (500 × 500 pixels) 
was placed on the section according to a random selection of x and 
y coordinates. This process was repeated seven times for each image 
of detrusor. The average optical density of LIF or gp130 expression 
in detrusor smooth muscle was then calculated. Expression of LIF 
or gp130 examined in the detrusor exhibited equivocal expression 
throughout detrusor of the dome, body, and neck of the urinary 
bladder; thus, data from each region are pooled and presented as 
LIF or gp130-IR above threshold in detrusor smooth muscle.
Suburothelial nerve plexus in urinary bladder whole mounts
The urinary bladder from control (n = 6) and experimental treatments 
(n = 6 each) was dissected and placed in Krebs solution. The bladder 
was cut open along the midline and pinned to a sylgard-coated dish. 
While pinned, the bladder neck on one side was notched for orienta-www.frontiersin.org  February 2011  | Volume 5  | Article 20  |  5
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4 h CYP treatment (Figure 1B). In contrast, no changes in CNTF 
mRNA expression in urothelium or detrusor smooth muscle were 
observed with CYP-induced cystitis of any duration (Figure 1C). 
Due to the absences of changes in CNTF mRNA expression in 
urinary bladder with CYP-induced cystitis (Figure 1C), no addi-
tional characterization of CNTF or the non-signaling α-receptor, 
CNTFRα, was performed.
Il-6rα, lIfr, gp130 transcrIpt expressIon In urothelIuM and 
detrusor sMooth Muscle WIth cyp-Induced cystItIs
The regulation of IL-6Rα, LIFR, gp130 transcripts was examined 
by Q-PCR analyses (Figures 1D–F) in urothelium and detrusor 
smooth muscle. IL-6Rα transcript expression significantly (p ≤ 0.01) 
increased in urothelium and detrusor smooth muscle with 4 h CYP-
induced cystitis compared to control (Figure 1D). IL-6Rα mRNA 
increased in urothelium and detrusor smooth muscle with CYP-
induced cystitis (4 h, 48 h, and chronic) compared to control 
(Figure 1A). IL-6 mRNA expression in urothelium or detrusor 
smooth muscle after 4 h CYP treatment was significantly (p ≤ 0.01) 
greater than the 48-h or chronic time point in the same tissues 
(Figure 1A). Q-PCR analyses demonstrated a significant (p ≤ 0.01) 
increase in LIF mRNA in urothelium and detrusor smooth muscle 
with CYP-induced cystitis (4 h, 48 h, and chronic) compared to 
control (Figure 1B). LIF mRNA expression in urothelium after 4 h 
CYP treatment was significantly (p ≤ 0.01) greater than the 48-h or 
chronic time point (Figure 1B). LIF mRNA expression in detru-
sor muscle was significantly increased with each duration of CYP 
treatment (Figure 1B) and the magnitude of change was consistent 
across time points. LIF mRNA expression in urothelium was signifi-
cantly (p ≤ 0.01) greater than that in detrusor smooth muscle with 
FIguRe 1 | Regulation of interleukin (IL)-6 type cytokines and receptors in 
urothelium and detrusor smooth muscle with cyclophosphamide 
(CYP)-induced cystitis. IL -6 (A), leukemia inhibitory factor [LIF; (B)], ciliary 
neurotrophic factor [CNTF; (C)], IL -6 receptor [R; (D)] α, LIFR (e), and gp130 (F) 
transcript level in control and after 4 h, 48 h, and chronic (8 days CYP-induced 
bladder inflammation. (A–F) Summary histograms of relative expression of the 
transcript expressed in urothelium and detrusor smooth muscle. Urothelium 
samples were set equal to 100% and normalized to the relative expression of 
the housekeeping gene, L32. Detrusor samples were expressed relative to 
urothelium samples and normalized to the relative expression of the 
housekeeping gene, L32. n = 6 for each group; *p ≤ 0.01 versus control or as 
indicated between groups by horizontal lines.Frontiers in Neuroscience  | Autonomic Neuroscience    February 2011  | Volume 5  | Article 20  |  6
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urothelIuM lIf-Ir In rats after InductIon of cystItIs
The expression of LIF-IR was very weak in the urothelium of 
urinary bladder whole mounts or cryostat bladder sections from 
control (Figures 3 and 4) rats. With acute CYP treatment (4 h), 
some diffuse LIF-IR was observed in the urothelium but more 
intense LIF-IR was observed in the lamina propria (Figure 3). 
Semi-quantitative analyses revealed significant increases in LIF-IR 
in the urothelium 4 h (p ≤ 0.05) and 48 h (p ≤ 0.01) after CYP 
treatment (Figure 3). Sustained LIF-IR was observed in the lamina 
propria (Figure 3) with CYP treatment. LIF-IR was significantly 
(p ≤ 0.01) increased in the urothelium with chronic CYP treat-
ment (Figures 3 and 4). No regional differences in LIF-IR in the 
urothelium of the dome, body, or neck regions of the urinary 
bladder were observed in control or CYP-treated rats. LIF-IR 
was observed in all cell layers (apical, intermediate, and basal) 
of the urothelium.
lIf-Ir In suburothelIal plexus WIth cyp-Induced cystItIs
In whole mount preparations, LIF-IR was infrequently and faintly 
observed in the suburothelial nerve plexus throughout the entire 
control urinary bladder (Figure 4). CYP treatment (48 h and 
chronic) increased the appearance of LIF-IR in the suburothelial 
plexus (Figure 4). The density of the LIF-IR in suburothelial nerve 
fibers was greatest in the neck region with CYP treatment and our 
analysis of CYP-induced effects was restricted to this region. A 
significant (p ≤ 0.01) increase in the density of the LIF-IR nerve 
fibers in the bladder neck region was observed with 48 h (4.5-
fold increase) and chronic (10.1-fold increase) CYP treatment 
(Figure 4). Fine and thicker caliber LIF-IR neuronal fibers were 
observed (Figure 4) in the suburothelial plexus with CYP treat-
ment. No changes in the LIF-IR suburothelial nerve plexus were 
expression in urothelium or detrusor smooth muscle after 4 h CYP 
treatment was significantly (p ≤ 0.01) greater than the 48-h or chronic 
time point in the same tissues (Figure 1D). With 4 h CYP-induced 
cystitis, IL-6Rα transcript expression was significantly greater in 
urothelium compared to detrusor smooth muscle (Figure 1D). 
Q-PCR analyses demonstrated a significant (p ≤ 0.01) decrease in 
LIFR mRNA in urothelium and 4 h CYP-induced cystitis compared 
to control; no differences in urothelium LIFR mRNA were observed 
at 48 h or chronic time points (Figure 1E). LIFR mRNA expression 
in detrusor with chronic CYP treatment was significantly (p ≤ 0.01) 
increased compared to control (Figure 1E). gp130 mRNA expression 
was significantly (p ≤ 0.01) increased in urothelium and detrusor 
smooth muscle with 48 h CYP treatment (Figure 1F); gp130 mRNA 
expression was significantly (p ≤ 0.01) greater in urothelium com-
pared to detrusor. gp130 mRNA expression was also significantly 
(p ≤ 0.01) increased in urothelium with chronic CYP treatment and 
expression was significantly (p ≤ 0.01) greater than that observed in 
detrusor smooth muscle (Figure 1F).
Il-6, lIf, and gp130 proteIn expressIon and effects of 
cyclophosphaMIde-Induced cystItIs In the Whole rat urInary 
bladder
 Interleukin-6, LIF, and gp130 protein expression increased sig-
nificantly (p ≤ 0.01) following 4 h (3.3- to 5.3-fold), 48 h (2.9- to 
3.8-fold), and chronic (2.2- to 2.3-fold) CYP treatment as deter-
mined with Western blot analyses (Figures 2A–D). Four hours CYP 
treatment induced the greatest upregulation of IL-6 (5.3-fold), LIF 
(3.5-fold), and gp130 (3.3-fold) expression, which was significantly 
(p ≤ 0.01) greater than expression after chronic CYP treatment 
(Figures 2B–D) and significantly (p ≤ 0.01) greater than 48 h CYP 
treatment in the case of IL-6 (Figure 2B).
FIguRe 2 | Interleukin-6, LIF, and gp130 protein expression in whole 
bladder using Western blotting. (A) Representative Western blot examples of 
IL -6, LIF , and gp130 expression in whole urinary bladders (25 μg) from control 
rats and those treated with cyclophosphamide (CYP) of varying duration. Actin 
expression was used as a loading control. (B–D) Summary histogram of relative 
IL -6 (B), LIF (C), gp130 (D) band density in each group normalized to total actin 
expressed as a percentage of control (no inflammation). CYP-induced cystitis 
significantly (p ≤ 0.01) increased IL -6, LIF , and gp130 expression in comparison to 
control urinary bladder. *p ≤ 0.01 versus control or as indicated between groups 
by horizontal lines. n = 6 for each group.www.frontiersin.org  February 2011  | Volume 5  | Article 20  |  7
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lIf-Ir In detrusor sMooth Muscle WIth cyp-Induced cystItIs
In urinary bladder sections from control rats, detrusor smooth 
muscle expression of LIF-IR was weak in all bladder regions exam-
ined (dome, body, neck; Figure 5). A significant (p ≤ 0.01) increase 
in LIF-IR in detrusor smooth muscle was observed in all urinary 
bladder regions and at all time points examined (4 h, 6.7-fold; 
48 h, 6.5-fold; chronic, 6.2-fold; Figure 5). No differential regional 
expression of LIF-IR in the detrusor muscle was observed with any 
duration of CYP treatment.
urothelIuM gp130-IMMunoreactIvIty In rats after InductIon 
of cystItIs
The IL-6 family of cytokines including IL-6 and LIF, form receptor 
complexes through different combinations of signaling receptor 
subunits with gp130 being used by all family members. Thus, in 
these studies, gp130-IR was characterized in urothelium, subu-
rothelial plexus and detrusor smooth muscle (see below) in control 
rats and in rats following CYP treatment of varying duration. The 
expression of gp130-IR was present in the urothelium of cryostat 
bladder sections from control rats being primarily present in api-
cal urothelial cells (Figure 6). With acute (4, 48 h) and chronic 
CYP treatment, gp130-IR was increased in the urothelium with 
gp130-IR being present in additional urothelial layers (i.e., interme-
diate; Figure 6). In urinary bladder from control and CYP-treated 
rats, no gp130-IR was present in the lamina propria (Figure 6). 
In addition, mo evidence of gp130-IR in the suburothelial nerve 
plexus was observed in cryostat bladder sections (Figure 6) or 
in whole mount bladder preparations (data not shown). Semi-
quantitative analyses revealed significant (p ≤ 0.01) increases in 
gp130-IR in the urothelium with CYP treatment (4 h, 48 h, chronic; 
Figure 6). No regional differences in gp130-IR in the urothelium 
of the dome, body, or neck regions of the urinary bladder were 
observed in control or CYP-treated rats.
gp130-IMMunoreactIvIty In detrusor sMooth Muscle WIth 
cyp-Induced cystItIs
In urinary bladder sections from control rats, detrusor smooth 
muscle expression of gp130-IR was weak in all bladder regions 
examined (dome, body, neck; Figure 7). CYP-induced cystitis sig-
nificantly (p ≤ 0.01) increased gp130-IR in detrusor smooth muscle 
in all urinary bladder regions and at all time points examined (4 h, 
5.7-fold; 48 h, 7.8-fold; chronic, 5.3-fold; Figure 7). No differen-
tial regional expression of gp130-IR in the detrusor muscle was 
observed with any duration of CYP treatment.
dIscussIon
These studies demonstrated upregulation of IL-6 and LIF transcript 
and protein expression in urinary bladder with CYP-induced cysti-
tis of varying duration. In contrast, no changes in CNTF transcript 
expression were observed in urothelium or detrusor smooth muscle 
with CYP-induced cystitis. Previous studies showed that blockade of 
JAK2 reduced urinary bladder hyperreflexia and referred, somatic 
sensitivity in CYP-treated rats (Cheppudira et al., 2009). LIF and 
IL-6 may represent two potential upstream mediators of JAK/STAT 
signaling. LIF protein expression was localized to the urothelium, 
detrusor smooth muscle, and suburothelial nerve plexus in uri-
nary bladder and expressed increased with CYP-induced cystitis. 
observed with 4 h CYP treatment (data not shown). LIF-IR in the 
suburothelial nerve plexus also exhibited IR for the pan neuronal 
marker, protein gene product 9.5 (PGP9.5; Figure 4).
FIguRe 3 | Leukemia inhibitory factor-immunoreactivity (IR) in cryostat 
sections of urothelium (u) after varying durations of CYP treatment. CYP 
treatment [4 h (B), 48 h (C,D), chronic (e,F)] significantly (p ≤ 0.05–0.01) 
upregulated the percent of LIF-IR in U in comparison control (A). Higher power 
fluorescence images of selected regions (white dashed boxes) in (C,e) are 
shown in (D,F). For all images, exposure times were held constant, and all 
tissues were processed simultaneously. In 4 h, 48 h, and chronic CYP-treated 
rats, LIF expression was visible in the U (B–F) and lamina propria [LP; (B–D)], 
whereas control (A) urinary bladder showed little or no LIF-IR. Calibration bar 
represents 50 μm in (A,C,e,g) and 25 μm in (B,D,F,g): Immunoabsorptions 
with LIF peptide (5 μg/ml) and antisera in bladder sections resulted in no 
staining above background. (H) Histogram of the percent of LIF expression 
above threshold in the urothelium of CYP-treated rats (4 h, 48 h, and chronic) 
expressed as a percentage of control. CYP treatment (4 h, 48 h, and chronic) 
significantly (#, p ≤ 0.05; *, p ≤ 0.01) upregulated LIF-IR in the urothelium. sm, 
smooth muscle. Data are a summary of n = 6 for each group.Frontiers in Neuroscience  | Autonomic Neuroscience    February 2011  | Volume 5  | Article 20  |  8
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Urothelial dysfunction has been proposed as an underlying cause 
or contributing factor in BPS/IC (Birder and de Groat, 2007). The 
cause(s) of this dysfunction is not known; however, several studies 
have shown that activation of bladder mast cells followed by release 
of  cytokines  contributes  to  urothelial  dysfunction  resulting  in 
abnormal bladder activity and pain (Sant et al., 2007). IL-6 expres-
sion is markedly increased in urine (Erickson et al., 2002; Sairanen 
et al., 2008) and urothelium (Peeker et al., 2000) of individuals with 
IC/BPS. Current studies suggest additional sources of cytokines and 
associated receptors to include the urothelium, detrusor smooth 
muscle, and suburothelial nerve plexus. Our immunohistochemi-
cal and Q-PCR data demonstrate that LIF and IL-6 protein and 
transcript expression are significantly increased in the urothelium 
and detrusor smooth muscle and LIF is additionally expressed in 
the suburothelial nerve plexus with CYP-induced cystitis. LIF and 
IL-6 transcript and protein expression were increased with acute 
(4 h, 48 h) and chronic (8 day) bladder inflammation. Changes in 
LIF mRNA and protein expression were largely complementary 
with CYP-induced cystitis. In contrast, CNTF mRNA expression 
was not changed in urothelium or detrusor smooth muscle with 
CYP-induced cystitis. This suggests that LIF and IL-6 contribute 
to both acute and chronic aspects of bladder inflammation and 
expression of these cytokines is found in multiple tissue sources 
in the urinary bladder.
A previous study from our laboratory demonstrated increased 
cytokine expression [e.g., interferon (IFN)-gamma, IL, and TNF-
α/β after CYP-induced cystitis; Malley and Vizzard, 2002]. A recent 
Changes in IL-6Rα, LIFR, and gp130 transcript expression were 
also identified in urinary bladder and changes in transcript expres-
sion were dependent upon duration of CYP-induced cystitis. gp130 
protein expression was also identified in the urothelium and detru-
sor smooth muscle but absent in the suburothelial nerve plexus. 
These studies extend the list of cytokines and associated receptors 
whose expression in urinary bladder is changed with urinary blad-
der inflammation.
Pain associated with BPS/IC may involve an alteration of 
visceral sensation/bladder sensory physiology. Altered visceral 
sensations from the urinary bladder (i.e., pain at low or moder-
ate bladder filling) that accompany BPS/IC (Petrone et al., 1995; 
Ho et al., 1997; Johansson et al., 1997; Driscoll and Teichman, 
2001; Sant and Hanno, 2001) may be mediated by many fac-
tors including changes in the properties of peripheral bladder 
afferent pathways such that bladder afferent neurons respond 
in an exaggerated manner to normally innocuous stimuli (allo-
dynia). The present studies suggest that LIF and IL-6, members 
of the IL-6 family of cytokines, produced in the urinary blad-
der after CYP-induced cystitis may also contribute to this sen-
sitization process and influence referred somatic sensitization 
and/or urinary bladder hyperreflexia in CYP-treated rats. The 
present study has demonstrated that a variety of urinary blad-
der components (urothelial cells, detrusor smooth muscle and 
bladder nerve fibers) express IL-6 and LIF and that transcript 
and protein expression is increased with CYP-induced cystitis 
of varying duration.
FIguRe 4 | Fluorescence photographs of LIF-immunoreactivity (IR) in 
urothelial cells and suburothelial plexus in the bladder neck region in whole 
mount preparations of the urinary bladder. In control (A) whole mount 
preparations, LIF-IR is weak compared to preparations from 48 h CYP-treated 
(B), and chronic CYP-treated (C) rats. LIF-IR in the suburothelial nerve plexus in the 
neck region increased in density with CYP-induced cystitis [48 h (e) and chronic (F)] 
compared to control (D). Arrows (D,e) and arrowheads (F) indicate small or large 
caliber LIF-IR nerve fibers respectively. With CYP treatment [chronic, (g–I)], LIF-IR in 
nerve fibers (g) in the suburothelial plexus exhibited complete overlap (I) with 
PGP9.5 (H), a pan neuronal marker. Calibration bar represents 80 μm.www.frontiersin.org  February 2011  | Volume 5  | Article 20  |  9
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1998). Our previous studies have demonstrated neurochemical 
plasticity in bladder afferent cells with CYP-induced cystitis that 
includes changes in neuropeptide expression (Vizzard, 2000c, 
2001; Zvarova and Vizzard, 2006) and bladder function improve-
ment with neuropeptide receptor blockade (Braas et al., 2006). It 
is possible that increased LIF and/or IL-6 expression in urinary 
bladder results in bladder hyperreflexia indirectly through subse-
quent upregulation of neuropeptides. Studies involving LIF- and 
IL-6 KO mice are necessary to address direct or indirect roles 
of LIF and IL-6 in bladder hyperreflexia and somatic sensitivity 
following cystitis.
The present study adds cytokines to the list of potential media-
tors that may contribute to altered micturition reflexes after cystitis. 
A significant body of literature exists to support the concept that 
cytokines are key signals that are released in the periphery, including 
the urinary bladder (Saban, 2001; Saban et al., 2001a,b), to signal the 
central nervous system that infection/inflammation has occurred 
(Lindholm et al., 1987; Dinarello, 1998; Poole and Woolf, 1998; 
Poole et al., 1998; Maier and Watkins, 1999). LIF and IL-6 transcript 
and protein expression in the urothelium and detrusor and the 
maintenance of the responses through acute, intermediate, and 
chronic CYP-induced cystitis suggest that IL-6 family members in 
particular, may contribute to neuroplasticity in lower urinary tract 
reflexes after cystitis. LIF modulates the initial neuroinflammatory 
response to neural injury and also regulates neuronal responses to 
injury through direct effects on immune cells (Gadient and Otten, 
1997) or through activation of neuropeptides (Rao et al., 1993; 
Corness et al., 1996; Sun and Zigmond, 1996a; Zigmond et al., 
1996). Although evidence suggests that LIF acts as a pro-inflamma-
tory mediator (Patterson, 1994; Sun and Zigmond, 1996b; Sugiura 
et al., 2000), other evidence indicates LIF functions as an anti-
inflammatory and analgesic cytokine (Ulich et al., 1994; Banner 
et al., 1998). IL-6, on the other hand, is generally considered to be 
pro-inflammatory (Gadient and Otten, 1997; Parkin and Cohen, 
2001) and has numerous biological activities including: promotion 
of neuronal survival, protection against neuronal damage, induc-
tion of neuronal differentiation, modulation of neurotransmitter/
neuromodulator synthesis, and modulation of pain (Gadient and 
Otten, 1997; Parkin and Cohen, 2001).
Individuals with BPS/IC report a predominance of suprapubic 
pain as well as urethral, genital, and non-genitourinary pain. In 
addition, hypersensitivity to somatic stimuli has been observed in 
subjects with BPS/IC (Fitzgerald et al., 2005; Ness, 2005). A number 
of reports have demonstrated referred somatic hypersensitivity in 
animal models of urinary bladder inflammation including CYP 
(Guerios et al., 2008; Studeny et al., 2008). In previous studies 
(Cheppudira et al., 2009), we demonstrated a reduction in hind 
paw sensitivity in rats treated with CYP (4 h) and a reduction in 
CYP-induced urinary bladder hyperreflexia when rats were also 
treated with a JAK2 inhibitor, AG490. In addition, blockade of the 
STAT3 pathway with AG490 attenuated mechanical allodynia and 
thermal hyperalgesia after peripheral nerve injury (Dominguez 
et al., 2008). Intrathecal IL-6 injection produces allodynia and 
hyperalgesia after peripheral nerve injury and intrathecal IL-6 
neutralizing antibody decreases allodynia (Arruda et al., 2000). 
The present studies have identified LIF and IL-6 as two potential 
upstream activators of JAK/STAT signaling in CYP-induced cystitis. 
study has also demonstrated upregulation of IL-6 transcript and 
protein expression in the submucosal layer of bladder after CYP 
treatment in mice (Nishii et al., 2006). The current demonstration 
of CYP-induced upregulation of IL-6 and LIF expression in the 
urinary bladder adds to the growing list of cytokines or chemokines 
that may play role(s) BPS/IC (Lamale et al., 2006) although some 
controversy exists relating to the usefulness of cytokines (i.e., IL-6) 
as a biomarker for BPS/IC (Daha et al., 2007). Our examination of 
LIF and IL-6 expression with bladder inflammation is consistent 
with previous demonstrations of LIF and IL-6 upregulation after 
peripheral nerve injury, inflammation (Banner and Patterson, 1994; 
Curtis et al., 1994; Patterson, 1994; Banner et al., 1998) or systemic 
inflammation (Brown et al., 1994).
Studies involving LIF knockout (KO) mice and pharmaco-
logical studies involving LIF and IL-6 administration to sensory 
neurons have demonstrated that both regulate neurochemical 
plasticity in dorsal root ganglion (DRG) and sympathetic neurons 
after peripheral nerve injury (Rao et al., 1993; Corness et al., 1996; 
Sun and Zigmond, 1996a; Zigmond et al., 1996; Thompson et al., 
FIguRe 5 | Fluorescence photographs of LIF-immunoreactivity (IR) in 
detrusor smooth muscle in the bladder neck region in whole mount 
preparations of the urinary bladder in control (A), 4 h CYP-treated (B), 
48 h CYP-treated (C), and chronic CYP-treated (D) rats. LIF-IR in the 
detrusor smooth muscle increased in density with CYP-induced cystitis (4 h, 
48 h, chronic). (e) Summary histogram of percent LIF expression above 
threshold in detrusor smooth muscle with CYP-induced cystitis. Data are a 
summary of n = 6 for each group. *p ≤ 0.01 versus control. Calibration bar 
represents 80 μm.Frontiers in Neuroscience  | Autonomic Neuroscience    February 2011  | Volume 5  | Article 20  |  10
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channels (Birder, 2006; Apodaca et al., 2007; Birder and de Groat, 
2007; Birder et al., 2009). The present demonstration of gp130 
protein and transcript expression as well as IL-6Rα and LIFR tran-
script expression in the urothelium extends the list of similarities 
between sensory neurons and urothelial cells as gp130, IL-6Rα, and 
LIFR are expressed in DRG cells (Gardiner et al., 2002). Although 
both Q-PCR and protein analyses of gp130 revealed increases in 
transcript and protein expression with CYP-induced cystitis, the 
time course of the increase differed. This difference may reflect 
earlier changes in post-translational processing compared to de 
novo transcription. Urothelial-mediated communication with the 
detrusor smooth muscle, suburothelial plexus, and/or interstitial 
cells has been suggested because of functional receptor expression 
and secretion capabilities of the urothelium (Birder, 2006; Apodaca 
et al., 2007; Birder and de Groat, 2007; Birder et al., 2009). IL-6 and 
LIF interactions with receptors (IL-6Rα, gp130, and LIFR) may 
facilitate the release of urothelial-derived mediators such as ATP, 
NO, or chemokines that may then influence the suburothelial nerve 
plexus to affect micturition function via urothelium-to-neuron 
communication (Birder, 2006; Apodaca et al., 2007; Birder and de 
Follow-up studies   involving IL-6 or LIF KO mice can be used to 
assess somatic sensitivity and bladder function in the presence and 
absence of urinary bladder inflammation.
Interleukin-6 and LIF form receptor complexes through differ-
ent combinations of signaling receptor subunits with the receptor 
subunit, gp130, being shared by all family members (Gadient and 
Patterson, 1999). CYP-induced cystitis increased gp130 expression 
in the urothelium and detrusor smooth muscle of the urinary blad-
der but expression was not observed in the suburothelial nerve 
plexus, largely composed of afferent nerve fibers (Andersson and 
Wein, 2004). Although gp130-IR was not found in the suburothelial 
nerve plexus, cytokine signaling via gp130 may contribute to func-
tional bladder sensory physiology via urothelium-mediated mecha-
nisms. The urothelium, once thought to provide an impermeable 
barrier only, is now suggested to have “neuron-like” properties such 
as plasticity and sensory, transduction, and signaling capabilities, 
especially in the context of bladder inflammation (Birder, 2006; 
Apodaca et al., 2007; Birder and de Groat, 2007; Birder et al., 2009). 
Urothelial cells share a number of similarities with sensory neu-
rons, including some consistency in the expression of receptors and 
FIguRe 6 | gp130-immunoreactivity (IR) in urothelium (u) and increased 
expression with CYP-induced cystitis. (A,B) gp130-IR in control U is weakly 
expressed and is restricted to apical urothelial cells (arrows). With 4 h (C,D), 48 h 
(e,F), and chronic (g,H) CYP-induced cystitis, gp130-IR is increased in intensity 
and additional urothelial layers (i.e., intermediate) express gp130-IR. gp130-IR is 
absent from the lamina propria (LP) of the urinary bladder from control or 
CYP-treated rats. (I) Summary histogram of percent gp130 expression above 
threshold in U with CYP-induced cystitis. Data are a summary of n = 6 for each 
group. *p ≤ 0.01 versus control. L, lumen. Calibration bar represents 80 μm in 
(A,C,e,g) and 45 μm in (B,D,F,H).www.frontiersin.org  February 2011  | Volume 5  | Article 20  |  11
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FIguRe 7 | gp130-Immunoreactivity (IR) in detrusor smooth muscle (sm) 
and increased expression with CYP-induced cystitis. (A) gp130-IR in 
control sm is very weakly expressed. With 4 h (B), 48 h (C–e) and chronic 
CYP-induced cystitis, gp130-IR is increased in intensity throughout the sm. 
(F) Immunoabsorptions with gp130 peptide (5 μg/ml) and antisera in bladder 
sections resulted in no staining above background. (g) Summary histogram of 
percent gp130 expression above threshold in sm with CYP-induced cystitis. 
Data are a summary of n = 6 for each group. *p ≤ 0.01 versus control. S, 
serosa. Calibration bar represents 80 μm in (A–C,F), 45 μm in (D), and 25 μm 
in (e).
Groat, 2007; Birder et al., 2009). Future studies determining IL-6- 
or LIF-induced release of ATP or NO using cultured rat urothelial 
cells can address this possibility. Given the increased expression 
of gp130, LIFR (chronic cystitis), and IL-6Rα in detrusor smooth 
muscle, cytokine/receptor signaling may also originate from the 
detrusor smooth muscle.
In summary, these studies have demonstrated significant altera-
tions in urinary bladder IL-6, LIF mRNA, and protein expression 
in urinary bladder following CYP-induced cystitis examined at 
three time points (acute, intermediate, and chronic). LIF protein 
expression was localized to the urothelium, detrusor, and subu-
rothelial plexus. Increased transcript expression IL-6 type cytokine 
receptors including IL-6Rα, LIFR (chronic cystitis), and gp130 
was also demonstrated in urinary bladder after CYP-induced cys-
titis. gp130 protein expression was localized to the urothelium 
and detrusor. Cytokines produced in the urinary bladder may, 
alone or in combination with other cytokines (Gadient et al., 1990; 
Woolf et al., 1997), chemokines (Arms et al., 2010), or neuro-
trophic factors (Poole and Woolf, 1998) also upregulated in the 
urinary bladder (Vizzard, 2000b), contribute to neurochemical 
(Vizzard, 1997, 2000c, 2001), electrophysiological (Jennings and 
Vizzard, 1999; Yoshimura and de Groat, 1999) and organizational 
(Vizzard, 2000a) changes demonstrated in the lower urinary tract 
following CYP-induced cystitis. Future studies are necessary to 
determine the functional contribution of LIF and IL-6 to neural 
plasticity after cystitis and subsequent activation of JAK/STAT 
signaling in urinary bladder using pharmacological approaches 
and/or LIF and IL-6 KO mice.
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